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Abstract
Determining and preserving the higher order structural integrity and conformational stability of 
proteins, plasmid DNA and macromolecular complexes such as viruses, virus-like particles and 
adjuvanted antigens is often a significant barrier to the successful stabilization and formulation of 
biopharmaceutical drugs and vaccines. These properties typically must be investigated with 
multiple lower resolution experimental methods, since each technique monitors only a narrow 
aspect of the overall conformational state of a macromolecular system. This review describes the 
use of empirical phase diagrams (EPDs) to combine large amounts of data from multiple high-
throughput instruments and construct a map of a target macromolecule's physical state as a 
function of temperature, solvent conditions, and other stress variables. We present a tutorial on the 
mathematical methodology, an overview of some of the experimental methods typically used, and 
examples of some of the previous major formulation applications. We also explore novel 
applications of EPDs including potential new mathematical approaches as well as possible new 
biopharmaceutical applications such as analytical comparability, chemical stability, and protein 
dynamics.
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Introduction
The pharmaceutical uses of proteins, nucleic acids and higher order macromolecular 
complexes such as viruses, virus-like particles, plasmid and polymer associations, and 
adjuvanted antigens represent the major advance in the biotechnology and vaccine industries 
in the last 30 years. Due to their more natural biological character, macromolecules offer a 
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degree of safety and efficacy that has resulted in their continuously increased use for a wide 
variety of therapeutic and prophylactic applications.
Traditional analytical methods of ensuring the structural integrity and conformational 
stability of these macromolecules have not, however, kept up with this progress. For 
example, due to the inability of individual experimental methods to monitor all aspects of 
the structural integrity of macromolecules, biological potency assays are required to ensure 
overall structural properties have been maintained. Moreover, in the case of protein-based 
drugs including monoclonal antibodies, loss of conformational integrity leading to 
aggregation during manufacturing and storage has raised potential safety concerns due to 
immunogenicity.1,2 This problem has become especially acute not only in terms of defining 
shelf life and ensuring proper administration, but it arises frequently as a comparability issue 
during the biopharmaceutical drug development process. For example, some of the 
challenges of establishing analytical comparability for different monoclonal antibodies 
during early and late stage development have recently been highlighted.3 With the advent of 
biosimilars, the ability to better define the higher order structure of proteins, nucleic acids, 
and macromolecular complexes in pharmaceutical dosage forms over time will most likely 
emerge as a critical analytical challenge.
Although at one time it was thought that it might be possible to build a “frame-work” type 
structure (especially with monoclonal antibodies) that would behave in a sufficiently 
uniform and reproducible fashion that a similar characterization and subsequent formulation 
process could be used with all homologues, it is clear that this is often not the case. This is 
actually evident when one considers that single mutations (think of sickle cell hemoglobin, 
cryommunoglobulins, many genetic diseases, etc.) can completely alter the physical 
properties of a macromolecule. Thus, each macromolecule, despite its apparent similarity to 
related molecules, must be treated as a physically independent agent.
Because the more complex three dimensional structures of macromolecules (typically 
involving tens of thousands of atoms or more) often play the key role in defining their 
biological activity and efficacy, characterization of higher order secondary, tertiary and 
quaternary structures remains a significant barrier to their pharmaceutical development. The 
problem is simple enough to state, although it remains difficult to address experimentally: 
How does one demonstrate that pharmaceutical macromolecular systems are sufficiently 
structurally similar (at the beginning and end of shelf life or in comparison to an analogous 
macromolecular systems) that they can for all intents and purposes be considered 
sufficiently identical for therapeutic use in terms of their safety, efficacy, and stability?
A number of standard methods currently exist with the ability to obtain high resolution 
structural information for proteins, nucleic acids and their complexes, resulting in commonly 
used representations such as stick and ball models, ribbon diagrams and van der Waals and 
electrostatic surface maps. Such three dimensional images of structure are the most common 
way to think of macromolecular systems. Among the experimental methods used to generate 
these images are X-Ray crystallography, nuclear magnetic resonance (NMR), cryo-electron 
microscopy and molecular mechanics calculations based on detailed force potentials. At 
present, however, these approaches are seldom directly applicable to biopharmaceutical 
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dosage forms due to practical limitations. For example, X-Ray crystallography requires 
crystallization, while NMR spectroscopy requires isotopic labeling and high concentrations. 
Moreover, complete structural characterization is most appropriate when it serves the overall 
goal of developing formulations. For these reasons, lower resolution biophysical methods 
are commonly employed to monitor structural integrity and hydrodynamic properties. These 
techniques include circular dichroism (CD), fluorescence, differential scanning calorimetry 
(DSC), chromatography, and light scattering, among others (see Table 1).
Unfortunately, no one method provides sufficient information to establish the identity and 
integrity of complex macromolecular systems. Therefore, the use of more than one of these 
methods is generally preferred to better characterize these entities. The multidimensional 
nature of such data sets makes adequate characterization of higher order structural integrity 
problematic. To develop stable dosage forms, formulation scientists typically collect data on 
stress-induced transitions in macromolecular structure under varying solution conditions and 
in the presence of different excipients. The data analysis is performed utilizing techniques 
that look at the data locally, such as visual inspection and/or mathematical fitting of thermal 
unfolding curves to sigmoidal functions. Unfortunately, the global features of high-
dimensional data spaces are not always revealed by such local data inspection. A more 
comprehensive analysis of the complex behavior typically observed is clearly desirable.
We review here the use of a global mathematical analysis technique developed for 
evaluation of large data sets generated from the biophysical analysis of biopharmaceuticals 
and vaccines. The mathematical methodology analyzes datasets, finding and quantifying 
multidimensional regularities that often are difficult to detect with local inspection. The 
mathematical information is converted into a visual map that serves to better define and 
investigate structural integrity and conformational stability of biomolecules and 
macromolecular complexes.
From the dozens of test cases to date, we find that these maps tend to be segmented into 
regions of distinct structural behavior. We call areas of a single contiguous color on these 
maps “apparent” phases, and the related diagram an empirical phase diagram (EPD). The 
word “empirical” serves to distinguish the diagrams from thermodynamic phase diagrams, 
in which the phase transformations are necessarily reversible. In spite of a common lack of 
reversibility in many protein transformations, the word “phase” to describe a physically 
distinctive form of a substance reasonably applies to a pharmaceutical usage, as described in 
more detail below.
An example is shown in Figure 1 of a representative dataset generated for a monoclonal 
antibody (IgG1), along with the resulting EPD. Various analytical methods were used to 
monitor both the structural integrity as well as the dynamic properties of the 
immunoglobulin as a function of temperature and solution pH.4 These data sets are then 
summarized for analysis in the form of an EPD. This approach has been applied widely by 
our laboratory to different proteins, plasmid DNA-lipid complexes, virus like particles and 
viruses. As shown in Figure 2, dozens of EPDs have been generated and published over the 
past 7-8 years. (Refer to Table 2 for references and more detailed information concerning 
each EPD. All EPDs in this article have been reformatted for uniform layout.)
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The EPD method has found many uses in the development and optimization of various types 
of biopharmaceutical and vaccine formulations. Empirical phase diagrams serve as guides to 
the interpretation of multidimensional data, determining regularities that may be difficult to 
visualize otherwise. These data sets are presented in an easy to inspect format, assisting in 
the determination of protein state and transition points as a function of environmental 
conditions such as temperature and solution pH. Many case studies have been published 
concerning not only the application of EPDs to various macromolecular systems, but also 
their extension by the addition of new biophysical measurement techniques and search space 
variables. Common pharmaceutical applications have been to aid in selecting stress 
conditions for excipient screening, finding optimal ranges of stabilizing solution conditions, 
and investigating the overall physical behavior of large macromolecular complexes. EPDs 
have been applied to the characterization, stabilization and formulation of proteins,4-21 virus 
like particles,22,23 viruses,24-27 nucleic acids and their complexes with lipid delivery 
vehicles,28 as well as whole bacterial cells.29 In principle, one can incorporate almost any 
kind of information into EPDs, including measurements of structural dynamics, chemical 
integrity or biological function. Empirical phase diagrams have also been shown to contain 
information concerning the functional and evolutionary relationships of proteins.10-12,16,17 
These applications will be discussed in more detail below.
The greatest potential application of the EPD method from a formulation development point 
of view, however, may be to drastically reduce the size of high throughput screening 
searches to identify stabilizing excipients. The accelerated time-lines of modern drug 
formulation efforts, and the complexity and size of the search spaces involved, typically 
result in suboptimal screening.5,30 The limited procedures available to screen a wide 
formulation design space can often result in suboptimal formulations or potentially even 
product failure during long term storage. A brute-force approach would test conformational 
and chemical stability at every relevant solvent condition. This approach is, however, cost 
prohibitive because of the exponentially large number of solvent conditions to test. For 
example, if one tested 5 different excipients at 4 different concentrations each, the number 
of combinations to test would be 45, or 1024 experiments. The use of empirical phase 
diagrams permits the size of these high throughput screening search spaces to be reduced in 
a very natural and pragmatic way. Using EPDs, macromolecule identity has been found to 
be conserved over contiguous regions of search space. The identification of unique and/or 
consistent conformational states reduces the search space from an exponentially large and 
unexplorable one to one that is much smaller yet adapted to the system of interest. More 
time consuming and extensive excipient screening and analytical characterization tests can 
then subsequently be performed on the smaller set of conditions to better design and develop 
optimized formulation conditions.
Experimental Methods
X-Ray Crystallography (XRC) and Nuclear Magnetic Resonance (NMR)
Since these two methods have the potential to determine the full three dimensional structure 
of macromolecules, they would be ideal were it not for confounding factors. Both methods 
require costly instrumentation and highly trained support staff. XRC requires the preparation 
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of crystals, which cannot always be grown, and do not necessarily represent structure in the 
solution state. The experimental procedure typically takes at least days to weeks to optimize 
and perform. Full structure determination by NMR currently takes a similar length of time, 
but only works for small to medium size proteins (thus not including monoclonal 
antibodies). Furthermore, isotopic labeling is necessary for full structural determination. 
These limiting aspects of NMR may, however, be reduced in the future.63,64 Both 
methodologies are also difficult to apply to pharmaceutical dosage forms due to interfering 
effects of excipients. The goal in the work described here is primarily to find transitions in 
higher order structure as a function of environmental conditions (e.g. temperature and pH in 
the presence of different excipients), which requires far less information than that required 
for full structure determination.
A wide variety of lower resolution biophysical techniques are available for characterization 
of biomolecules and their macromolecular complexes. In general, these methods can be 
employed over a wide range of concentrations (from a few micrograms to hundreds of 
milligrams per milliliter), although interference by factors such as light scattering, 
absorbance flattening and solute interference can sometimes be a problem. Very brief 
descriptions of many of these techniques now follow. References and a summary of the 
capabilities of each method are shown in Table 1.
Near and Far Ultraviolet Absorbance Spectroscopy (UVAS)
Both proteins and nucleic acids contain a number of environmentally sensitive 
chromophores which absorb in the UV region. While the peptide bonds of proteins display 
intense absorbance in the far UV (180-220nm) region, thus yielding secondary structure 
information, analysis in this region is normally done by circular dichroism or FTIR due to 
their better resolution (see below). In contrast, derivative analysis of protein spectra in the 
near UV typically provides 5 to 6 well resolved peaks from the three aromatic residues 
(Trp,Tyr,Phe), which are quite sensitive to structural changes. Nucleic acids also produce 
distinct spectra from the bases in the same spectral region, which can be used to follow 
structural alterations. Conveniently, when a macromolecular system aggregates, optical 
density (OD) in non-absorbing regions (>340nm) can be used to monitor this phenomenon 
simultaneously with near UV spectral analysis.
Near and Far Ultraviolet Circular Dichroism (CD)
Due to the high optical activity of helical structures, CD can be used to detect changes in 
both nucleic acid and protein secondary structure in the far-UV region for proteins and mid-
UV region for nucleic acids. The optical asymmetry of the environment of the aromatic side 
chains in proteins also produces distinct signals typically of some complexity in the near-UV 
region. Thus by monitoring both regions, structural changes in secondary and tertiary 
structure can be detected. Deconvolution analysis of CD spectral shape in the far UV region 
also allows fairly accurate estimates (within 2-3%) of actual secondary structure content. 
The induced CD of certain dyes can also be used to determine structural information, 
especially with nucleic acids and polysaccharides.
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Intrinsic and Extrinsic Fluorescence
The intrinsic UV fluorescence (UV-IF) of proteins is dominated by emission from indole 
side chains when Trp residues are present and not endogenously quenched. Such 
fluorescence is very environmentally sensitive, making the peak position and intensity of 
Trp fluorescence a particularly useful probe of protein structural change. The use of 
extrinsic fluorescence (EF) probes is applicable to virtually all forms of macromolecules and 
their complexes, including proteins, nucleic acids, and membranes. For example, dyes are 
available which are particularly attracted to apolar regions in proteins as well as the 
characteristic intermolecular β-structures which often form when proteins associate. A wide 
variety of fluorophores bind both within nucleic acid grooves as well as between bases 
(intercalation). In addition, there exist a large number of dyes that interact with lipid bilayers 
such as those present in some viruses and virus-like particles as well as bacterial cells. Some 
of the most commonly used dyes are 8-anilino-1-naphthalenesulfonate (ANS), used in 
protein studies; laurdan, used for lipid bilayers; and YOYO-1, used for DNA. In all of the 
above cases, large changes in fluorescence intensity, peak position, and polarization often 
occur as these dyes bind to their various targets. Thus, they can be used to probe a plethora 
of aspects of macromolecular structure and associated changes.
Infrared and Raman Spectroscopy
The complex series of vibrational transitions present in macromolecules can be used to 
obtain structural information from either infrared or Raman spectroscopy. Infrared 
spectroscopy is performed almost exclusively in a Fourier transform mode (FTIR). While 
FTIR is an absorptive technique and Raman is a scattering measurement, both have 
significant although sometimes different utility. Each can be used to examine the secondary 
structure of both proteins and nucleic acids (as well as complexes such as viruses) through 
deconvolution of constituent amide bands (signals from peptide bonds and various nucleic 
acid base signals). FTIR is the more widely used technique due to instrument availability 
and sensitivity. In contrast, signals from side-chains tend to be much better detected in 
Raman spectra.
Static and Dynamic Light Scattering (SLS, DLS)
The size and shape of macromolecules both in their monomeric and associated forms can be 
characterized by static and dynamic light scattering. In the former, the intensity of the 
scattered light is measured (often as a function of angle), while in the latter, fluctuations in 
intensity of scattered light due to Brownian motion are analyzed. Size and shape information 
obtained are model dependent and complicated by the presence of non-homogeneous 
scatterers, although various data analysis methods exist to produce useful numerical values 
from both methods. Imposition of an external electromagnetic field can be used to obtain 
zeta-potential values. A method we do not discuss here is analytical ultra-centrifugation 
(AUC). Although AUC is very information rich in terms of evaluating hydrodynamic 
properties of biomolecules and macromolecular complexes, this methodology is not 
available in a high throughput mode, unlike the scattering based methods.
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Differential Scanning Calorimetry (DSC)
By measuring differential heat capacities in macromolecules, transitions in state can be 
detected. Virtually every biomolecule from proteins and nucleic acids to membranes and 
viral particles undergo thermally induced transitions that can be detected by this method and 
used as indicators of thermal stability. Like the methods described above, DSC is now 
available in a high throughput mode making it useful for the formulation and stability 
purposes discussed below.
High Performance Liquid Chromatography (HPLC)
Although not generally adaptable to a high throughput mode in the sense of the above 
methods (i.e. one cannot easily and rapidly perform measurements over a wide range of pH 
and temperatures), the use of auto-samplers does permit a variety of chromatographic 
methods to be used after exposure to a wide range of conditions. Probably the three most 
useful to the formulation scientist are size-exclusion (SEC), ion-exchange (IE), and reversed 
phase (RP) chromatography. All three methods will be well known to most readers so we 
just mention their applicability to size, charge, and polarity changes, respectively. To 
characterize chemical degradation (oxidation, deamidation, hydrolysis, etc.), RP-HPLC is 
commonly used in combination with fragmentation and mass spectrometry to characterize 
sites of covalent alteration. Methods such as capillary isoelectric focusing are also 
commonly used for this purpose.
Measurements sensitive to intramolecular dynamics
It has become increasingly apparent that macromolecular stability is dependent on the 
various types of internal molecular motions present in macromolecular systems, such as 
side-chain movements, breathing modes, domain motions, etc. Thus, measurements of such 
motions should ultimately be included in a thorough analysis of stability. A number of 
methods are available for this purpose, and can sample a wide range of such motions. 
Methods specifically designed for this purpose such as isotope exchange and various forms 
of NMR are not generally applicable to high-throughput applications, although this may 
change in the future. In contrast, a number of high-throughput methods are available, 
including ultrasonic spectroscopy (to measure compressibility), pressure perturbation DSC 
(to measure coefficients of thermal expansion), as well spectral approaches such as 
temperature induced pre-transition peak shifts in second derivative UV absorbance spectra, 
fluorescence anisotropy (rotational correlation times), red-edge fluorescence excitation, and 
fluorescence and UV absorbance solute-induced spectral shifts.
Multi-mode Machines (“Protein Machines”)
Instruments are currently being developed by several vendors that simultaneously collect 
data using several of the above methods. For example, the Chirascan from Applied 
Photophysics collects near and far UV CD and near and far UV absorbance. Fluorescence 
emission spectra can also be collected, although not simultaneously with the other 
techniques. The Protein Machine from Olis Instruments collects far UV CD, near UV 
absorbance, fluorescence emission and excitation spectra, and red-edge excitation spectra. 
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Both instruments can also acquire light scattering signals during several of these 
measurements.
Simultaneous near and far UV measurements require intermediate path lengths and 
concentrations. In the far UV region, peptide bonds yield very strong absorbance. Longer 
path lengths or higher concentrations produce excess absorbance, causing absorbance 
flattening in far UV measurements. To avoid absorbance flattening in this region one must 
use short path lengths or low concentrations. The near UV absorbance spectra of aromatic 
residues are comparatively weak, so short path lengths or low concentrations yield too little 
signal, resulting in a significant amount of noise in near UV measurements. It is not possible 
in principle to find an optimum tradeoff between path length and concentration, because 
both have the same effect on absorbance. Changing slit widths can overcome these problems 
to only a very limited extent. Thus, the existence of conflicting requirements makes it 
technically difficult, but not impossible, to simultaneously collect data in the near and far 
UV regions. Nevertheless, these instruments do permit simultaneous collection of data from 
multiple techniques with good to excellent resolution. In combination with multiple sample 
holders, EPDs can be obtained directly from such instruments over periods of 3-12 hours.
Currently, the only way to simultaneously collect data in the near and far UV is to use very 
long integration times in the near UV, to reduce excessive noise. These long integration 
times offset the time saved by simultaneous collection. Short of waiting for instruments with 
lower noise to be developed, there is at least one possible option to be considered: variable 
path length cells would permit automatic adjusting of absorbance for each wavelength range. 
This feature is available in a few UV-Vis absorbance instruments built for measuring 
concentrations, and could potentially be applied to multi-modal spectrometers.
Data Interpretation Challenges
One accumulates a wealth of data when several of the above methods are employed under 
varying environmental conditions. Figure 1A-F shows one of these data sets for an IgG 
molecule.4 Data were collected as a function of temperature and pH, from pH 3 to 8 at one 
pH unit increments (6 different conditions), and temperatures from 20 to 90°C at 2.5°C 
intervals (29 different conditions), resulting in a 6×29 assay grid. At each point on this grid, 
measurements were taken of CD molar ellipticity at 218 nm (Panel A), intrinsic fluorescence 
peak position and intensity (Panels B and C), tryptophan fluorescence lifetime (Panel D), 
static light scattering (Panel E), and ANS fluorescence intensity (Panel F).
The data set shown in Figure 1A-F presents challenges as well as opportunities. 
Traditionally, we look for evidence of conformational changes, unfolding, and aggregation, 
then estimate transition temperatures. This approach suffers three major drawbacks. First, 
experimental methods sometimes disagree on transition temperatures and protein state. 
Second, plots like Figure 1A do not convey much information to the non-expert. Third, 
important variations and/or regularities in the data may not carry through to the final 
analysis when they are unexplained, too complex to easily observe, or partially hidden by 
noise.
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Each experimental technique provides a picture of one or more different aspects of a protein 
or other macromolecular system. The formulation scientist must assemble this information 
into an overall picture of the behavior of the protein. The situation is similar to the tale of the 
blind men and the elephant (e.g., “The Blind Men and the Elephant: A Hindu Fable”, a 
poem by John Godfrey Saxe), where the macromolecular drug is the elephant, and the 
experimental methods are the blind men touching different parts of the elephant (tusk, trunk, 
ear, tail, etc). The formulation scientist is the one who must assemble the information from 
the others and decide what the elephant looks like. When experimental methods disagree, 
the formulation scientist must make an educated guess. Sometimes even a single method 
will report conflicting information, as when transition temperatures between folded and 
unfolded conformations of a biomolecule differ for measurements from two different 
wavelengths during the same circular dichroism temperature melt experiment.
Although each experimental method is sensitive to different aspects of protein behavior, 
different methods often provide overlapping information as well. This manifests itself as 
regularities in the combined data sets. One would not expect these regularities to always be 
easily visible in data such as that shown in Figure 1A-F. In these plots we show the results 
from six biophysical methods to monitor the higher order structure of an IgG molecule as a 
function of pH and temperature. Similar experiments can generate even larger data sets with 
many more instruments and/or environmental conditions. To find the regularities, we would 
need to find patterns in a high dimensional space. This is not possible in the simple plots of 
Figure 1A-F. An empirical phase diagram of the data in Figure 1A-F is shown in Figure 1G 
(Figure 1H will be discussed in the applications section). The red region of Figure 1G tells 
us that high temperature behavior is clearly different between low and high pH (pH values 
above 4). Inspecting the data, the distinction appears to be subtle and complex, but the EPD 
shows us that in the multidimensional space, the difference is actually pronounced. 
Furthermore, focusing on measurements at pH 3 (shown in black), we see that the positions 
of transitions near 40°C are not well defined. On the phase diagram, the transition is sharper 
and positioned near 40°C.
Formulation scientists must often resort to educated guesses when further information is 
hidden in the complex data sets generated from a series of measurements.EPDs use the 
results of a global analysis, increasing the use of information and reducing the role of 
guesswork. Such plots present the results in a simple format, so the eye of a non-expert can 
pick out regularities and transitions with little difficulty.
Mathematical Methods
Search space, protein phase space, and measurement phase space
To better understand the mathematical aspects of generating empirical phase diagrams, we 
first review terms and concepts that arise naturally from the quantitative characterization of 
large data sets. Each mathematical term can be made as formal as desired, which we avoid 
here. Instead, our emphasis is on conveying relevant concepts by using precise mathematical 
terms in a manner as informal and pictorial as possible.
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The seach space is defined by the experimental control variables. One may use virtually 
anything as a control variable, such as concentrations of excipients, temperature, pH, or 
variables describing protein history. We cannot test every point in the space, so one usually 
forms a grid of points to test. We will call this the “search grid”. The terms “search space” 
and “search grid” are borrowed from the field of protein crystallization. In Figure 3A, a one 
dimensional grid has been chosen consisting of 4 pH values. If we had varied both solution 
pH and temperature, we would have needed two variables to define the solvent state, and we 
would have tested points in a two dimensional grid (as will be discussed later in Figure 6A).
Macromolecule phase space
The state of a target biomolecule or macromolecular complex can be described by a list of 
numbers. For example, we can use a long list of the positions of all the atoms in a protein.65 
If we consider each list as a point in a high dimensional phase space, then changes in protein 
shape equate to movement of the corresponding point in phase space. In Figure 3A we have 
illustrated a protein phase space with ratios of secondary structure. An exhaustively 
complete protein phase space would require thousands of variables to completely describe a 
protein state.
Preferred molecule states correspond to equilibrium points caused by energy minima in 
phase space. Due to thermal vibrations, the molecular states fluctuate around these energy 
minima, and can be visualized as a cloud of points around each minimum, usually described 
by a Boltzmann distribution56,65,66.
For a given solvent condition, there can also be more than one accessible stable protein state, 
due to the existence of multiple minima in the protein energy landscape.65 Instead of a 
single cloud of points for the given solvent condition, there may be several (see Figure 3A, 
pH 5 and 6). When we collect spectroscopic data, we see the average of the contributions 
from all the protein states.
Measurement phase space
This space is defined by all of the measurements used to probe a macromolecular state. For 
example, in Figure 3B we show how 2 measurements define a 2 dimensional measurement 
space. If we collect CD data at 3 wavelengths and UVAS data at 2 wavelengths, we can join 
these into a single 5 dimensional vector (as will be discussed in more detail later; see Figure 
6B).
The measurements in a data set contain information generated by multiple physical 
processes. The types of information derived from these physical processes possess varying 
levels of prominence in the data. Some stand out on their own, while others require 
extensive processing to isolate.
We also attribute varying levels of significance to the different types of information. For 
example, for formulation purposes, information concerning aggregation is highly significant, 
while information concerning protonation may be less so.
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Since the data are generated by physical processes, one cannot expect prominence to be 
related to significance. Thus, data usually require a certain amount of preprocessing.
Data preprocessing
Data preprocessing steps are designed to extract significant information from data in which 
it may be hidden in complex ways amid less important information. Preprocessing usually 
consists of finding the position, width, or intensity of spectral or calorimetric peaks, using 
methods such as second derivative processing, Fourier self deconvolution, or determination 
of the spectral center of mass. Another preprocessing practice is the hand-selection of data 
that is deemed to be pertinent, information rich, and sufficiently free of noise.
For example, the simulated data in Figure 3B is similar to preprocessed data from near 
UVAS second derivative peak position analysis. A spectrum would have been collected and 
preprocessed for each pH value, yielding the positions of several peaks. Selection of two of 
the peaks would have resulted in a data set like the one plotted in Figure 3B.
Typically, on the order of ten measurements remain after preprocessing. It is best to not 
overdo preprocessing, which may erase information about transitions. Preprocessing 
constitutes a bias concerning the significance of types of information, so it must be applied 
judiciously. An example of extreme preprocessing would be to take an FTIR absorbance 
spectrum measured at 3000 frequencies and reduce it to a single frequency. The global 
analysis we will describe is capable of finding optimal low-dimensional representations of 
high dimensional data, and tends to perform better when a large number of measurements 
are used.
Data standardization
Preprocessing results in a collection of numbers that cannot be expected to have appropriate 
units, scales, or dimensions. The units of most data are standardized by scientific and 
engineering conventions that have no relation to their significance for formulation 
development. For example, fluorescence emission photon peak counts of proteins tend to 
range from 104 to 106, but absorbance values tend to be kept below 1 AU. The scale of data 
must be adjusted so that artificial unit conventions do not cause one type of data to 
overwhelm another. Furthermore, mathematics alone does not contain knowledge of 
formulation, so it cannot in principle determine the scale choices, preprocessing, and 
standardization that will lead to useful summaries. Perhaps surprisingly, once these choices 
are made by the user, mathematics can determine optimal low dimensional representations 
of data. Fortunately, the adjustment of scale variables is straightforward as described below 
and rather robust outcomes are not difficult to obtain.
We now discuss an example of the influence of scales on estimates of transition values. 
Figures 3C and 3D illustrate how measurements can disagree on the position of transitions. 
Plotting the measurements separately, measurement 1 (Figure 3C) shows a transition 
between pH 5 and 6, but measurement 2 (Figure 3D) shows a transition between pH 6 and 7. 
The two dimensional plot (3B) shows the largest transition between pH 6 and 7. 
Measurement 2 dominates the two dimensional plot since that peak's variation stretches over 
a larger range.
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Our current approach to resolving the conflict is to resize the variation in each measurement 
so that they have equal magnitude. There are many ways to do this, and we show only one 
of them. Since we are only interested in transitions, we begin by centering the measurements 
at the origin by subtracting the mean measurement within each measurement type (Figure 
4A). This is done separately for each measurement type. Then we can normalize each 
measurement to equalize their variation (Figure 4B). This is also done separately for each 
measurement type. We see in Figure 4B that the largest transition occurs between pH 5 and 
6.
Singular Value Decomposition
Once the data has been processed and standardized, we seek a way to visualize and inspect 
it. Since the data set is high dimensional (usually around 10 numbers per search grid point) 
the human eye cannot find its patterns. Humans prefer two-dimensional diagrams. Thus, a 
method is required to lower the dimensionality of data for visual representation.
Hypothetically speaking, if humans could only perceive one dimension, we would want to 
represent the data in one dimension while preserving the information content as much as 
possible. A standard way to reduce the dimensionality of data is called the Singular Value 
Decomposition (SVD). Figure 4C conceptually illustrates the result of applying SVD to a 
data set. We begin with points in a 2 dimensional space (the black dots), and we seek to 
project the data onto an optimal 1 dimensional space. The term “optimal” is defined by 
minimizing the projection error, indicated by the red lines. SVD gives us the optimal 1 
dimensional space, shown as a blue line. This is still, however, a 2 dimensional plot. For a 1 
dimensional plot, we can plot the distance along the blue line (the position inside the 1 
dimensional space). This is shown in Figure 4D.
The entire procedure we use to project data is known as Principal Components Analysis 
(PCA). PCA consists of subtracting the mean from a data set and applying SVD. These steps 
are shown in Figure 4A and 4C. The extra step of normalizing the measurements, shown in 
4B, is a known extension to PCA.
We illustrate higher dimensional SVD with another simple example (Figure 5). Some 
familiarity with linear algebra will assist the reader, but the following discussion should also 
be accessible to a general audience. Suppose we are given the following measurements of a 
protein at different temperatures.
Δλ1 Δλ2 Δλ3
10°C 3 −2 −1
30°C 2 −1 −3
50°C 0 −1 −1
70°C −3 1 2
90°C −2 3 3
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For instance, the data might represent second derivative ultraviolet absorbance peak shifts in 
hundredths of a nanometer.
A plot of this data is shown in Figure 5A. Each row is plotted as a point in three dimensions, 
and each point corresponds to a different temperature. The data is three dimensional in the 
sense that at each temperature we have three numbers, Δλ1, Δλ2, and Δλ3, which represent 
the state of the target molecule.
If we could perceive two dimensions but not three, the transition between 50°C and 70°C 
might be difficult to see. So we would want to reduce the data to two dimensions in a way 
that optimally retains the information in the original data set. To see how to do this, refer to 
Figure 5B. The black points are the data points, and the pink area represents a plane. The red 
points are the positions within the plane that are nearest to the data points. They are two 
dimensional approximations to the data points. The red lines represent the error in the 
approximation. We seek the plane which minimizes the total error, defined as the sum of the 
squares of the lengths of all of the red lines.
To show how this works, we first express the data as a matrix:
SVD finds an optimal, unique two dimensional approximation, which we will call D̃
(For readers familiar with the terms, we note that the matrix A consists of the left singular 
vector matrix multiplied by the singular value matrix, and retains only the top 2 singular 
vectors. We have done this to simplify the presentation. For a summary of the properties of 
SVD, see the appendix.)
Maddux et al. Page 13






















The two rows of the matrix X are perpendicular to each other. In Figure 5B, the two rows of 
X are represented as blue vectors. They are axes in a two dimensional plane (shown in pink), 
and serve to define that plane. This plane is the unique plane that minimizes the total error. 
When we perform the matrix multiplication AX, each row of A specifies a linear 
combination of the rows of X. The matrix multiplication places the approximated data points 
within the plane defined by the row vectors of X.
In this example, SVD actually returned three optimal axii and we have chosen and shown 
only the two most important ones (the two rows of X, shown as blue vectors in Figure 5B). 
When we choose optimal axii to define the lower dimensional space, we generally discard 
the other axii returned by linear algebra. If we had used only the first row of X, we would 
have approximated the data within a one dimensional space (Figure 5D). In that case, the 
error would have been larger. (On the other hand, the optimal one dimensional axis may 
well encompass most of the data, depending on the relative magnitude of the singular 
values.)
When we use all of the axii given by SVD, there is no error, and the approximation D̃ is 
equal to the original matrix D. Error results from excluding axii, as we have done in Figures 
5D and 5B. If we exclude axii that only result in a small increase in error, the approximation 
D̃ can be very close to the original matrix D.
For many data sets, the most common result is that only a few of the axii are important, 
resulting in a large increase in error when they are dropped. The rest of the axii can usually 
be eliminated with very little effect on the approximation. We can choose in advance the 
number of axii to use. In this example, we have three dimensional data that we want to 
reduce to two dimensions. We can minimize the error for a two dimensional projection by 
using the two most important axii returned by SVD.
Since we want a true two dimensional representation of D, it is self-consistent to use the 
positions within the optimal plane instead of the three dimensional positions. The two 
dimensional positions within the plane are given by the matrix A, and are plotted in Figure 
5C. Each point in Figure 5C represents a row of A.
The error in the approximation from D to D̃ can be defined numerically. It is the sum of the 
squares of the lengths of all the error vectors (the red lines in Figure 5B). This is the error 
that SVD minimizes. It can be expressed as
To quantify how well the data has been approximated we compute the percent error, defined 
as:
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It is important to note that the procedure gains its power from the fact that it works the same 
way in higher dimensions. Instead of three peak shifts, as in the previous example, we might 
be given 5 measurements at each temperature. These are vectors in a five dimensional space. 
After standardization, we apply SVD to the matrix of data, returning up to 5 axii. The most 
significant axii are then used to define a lower dimensional space. The projection onto that 
space is the best possible approximation to the data that can be made based on the number of 
dimensions retained. Just as in the example above, the approximated matrix still appears 
high dimensional. Yet we can get a true low dimensional view of the data by using the data 
point positions within the space defined by the retained axii (as illustrated for two 
dimensional projections in Figure 5C).
The Empirical Phase Diagram
We begin by choosing a search grid (Figure 6A). The most common search grid previously 
used for protein phase diagrams covers pH values from 3 to 8 in one pH unit increments and 
temperatures from 10 to 85°C in 2.5°C increments. Measurements typically include a series 
of biophysical techniques such as CD, fluorescence, and UV absorbance spectroscopy as 
well as light scattering. In this simulated example, we choose a simpler case of two pH 
values (5 and 6) and two temperature values (10°C and 50°C) as measured by CD (at 3 
wavelengths) and UVAS (at 2 wavelengths).
After collecting and preprocessing the data, a matrix is created in which the rows correspond 
to all search grid positions and the columns correspond to all measurement types (Figure 
6B). The matrix is standardized and projected down to 3 dimensions (as described in the 
previous section). The result of standardization and projection is shown in Figure 6C. The 
number of rows remains the same but the number of columns has been reduced to 3.
To provide a convenient visual image, the resulting 3 dimensional positions are converted 
into ratios of red, green and blue color. First the data is shifted and resized so that all the 
numbers fit in the range (0,1) (Figure 6D). Then the 3 dimensional positions are expressed 
as colors. To create the phase diagram, the colors are reorganized into a grid and plotted 
(Figure 6E).
History
It should be mentioned that the singular value decomposition is attributed to the 
mathematicians Beltrami and Jordan, who discovered a version in the 1870's. The physicist 
Carl Eckhart is credited with extending the procedure to non-square matrices. It seems to 
have been re-discovered many times, and is sometimes associated with Householder and 
Karhunen-Loeve67.
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A technique similar to our procedure was used in 1989 to merge satellite imagery.68 It is 
called “PCA based image fusion”, is widely employed in geo-sensing and in-vivo 
imaging,69,70 and is spreading to other areas such as art conservation and astronomy.71,72 
Unaware of this history, we first applied PCA in 2003 to characterize transitions in higher 
order protein structure under different environmental stresses6.
Interpreting Empirical Phase Diagrams
Once the empirical phase diagram has been generated, the mathematical work is done. What 
remains is interpretation. The first step is to inspect the phase diagram to determine regions 
of conserved structure. Areas of search space that produce similar measurements in the 
abstract 3-dimensional space manifest themselves on the phase diagram as areas of a single 
contiguous color. Transitions are then manifested as changes in color, with noise showing as 
irregular and often quite subtle color variation. When clear structural transitions are not 
evident, the phase diagram can be dominated by effects unrelated to the higher order 
structure of the target macromolecule, such as a decrease in absolute fluoresence intensity 
with rising temperature.
Once the EPD has been inspected to determine regions of conserved structure, one tries to 
determine as much as possible about the actual physical state of the protein or 
macromolecular complex within those regions. To do this, one must refer to the original 
measurements and consider the physical processes that generated them. To reiterate, the best 
one can hope from quantitative analysis is optimal projection, which still needs expert 
scientific evaluation of the original biophysical data, and perhaps further targeted 
experimentation. By referring back to the source data, empirical phase diagrams can usually 
be segmented into the following types of structure: low temperature inactive, active form, 
molten globule states, high temperature or acidic pH unfolded forms, and forms which are 
aggregated or dissociated to various extents. Sometimes, however, a region of an EPD may 
have no ready interpretation, indicating that the data and mathematics have found something 
the expert does not readily recognize.
The color of an area is itself a “code”, not universally meaningful information. To get an 
idea of why this is, refer to Figures 5B and 5C. PCA gave the two vectors X1 and X2, 
defining a plane for the optimal two dimensional projection. An entirely different data set 
projected into 2 dimensions will also give an optimal plane whose absolute orientation 
relative to the first cannot be known without comparing the sets with each other. Thus, two 
different meanings can (and generally will) be applied to a given color code. This is not a 
matter of much concern, because the color code is not actually used in a quantitative 
analysis. The colors serve no purpose other than to identify areas of different behavior. One 
might just as well have labeled contiguous regions with names or numbers, as in traditional 
thermodynamic phase diagrams.
While the results of PCA are unique for any given data set, small changes in a data set can 
sometimes result in rotation of the principal axii. That will occur when two large, important 
singular values are nearly equal. Then distinguishing them by size-ordering can hinge on 
small variations. The result of swapping the order of axes is a swap of two colors. The 
shapes of the regions and transitions will, however, remain the same, because the projection 
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plane in question is an absolute concept that does not depend on the labeling. Notice in 
Figure 5C that a deliberate rotation of X1 and X2 does not alter any information about the 
transition.
In a study of Clostridium difficile toxins and toxoids, discussed below, phase diagrams were 
generated jointly to achieve uniform meaning of their colors.16 In such an analysis, the 
target macromolecule becomes one of the control variables. For example, if the control 
variables had been pH and temperature, they will now also include the target 
macromolecule. The matrix shown in Figure 6B will contain additional rows to incorporate 
the increased number of combinations of control variable positions. The matrix is then 
standardized, projected into 3 dimensions, rescaled, and interpreted as colors, as shown in 
Figures 6C and 6D. Finally, the colors are made into multiple phase diagrams, one for each 
target macromolecule.
Applications and Case Studies
Here we summarize some applications and case studies using empirical phase diagrams to 
formulate and stabilize various biomolecules and larger macromolecular complexes. As 
highlighted earlier, common pharmaceutical applications have been to select stress 
conditions for high throughput excipient screening, to find ranges of solution conditions 
resulting in optimized stability, and to investigate the overall structural integrity and 
conformational stability behavior of large macromolecular complexes.
Selection of stress conditions for excipient screening
Screening compounds and polymers for stabilization of a liquid formulation of a 
biomolecule or macromolecular complex is a time consuming process due to both the large 
number of excipients that should be tested, and the time it takes to complete each test. The 
latter can be reduced by selecting conditions which accelerate degradation processes 
(although the danger always exists that the degradation reactions induced may not be 
directly relevant to actual storage conditions). The EPD approach can be used to select these 
accelerated conditions. Since each region of color in an EPD represents a different state of 
the system, it is presumably related to a local minimum in the energy landscape. Thus, at 
transitions between these regions, the system may have a somewhat higher energy and be 
farther from equilibrium. This makes it more likely (but not guaranteed) that the system can 
access other minima in the energy landscape under these conditions. By selecting transition 
conditions within pharmaceutically accessible regions, it seems probable that relevant 
degradation mechanisms during real time storage will be enhanced under these accelerated 
conditions. This basic concept has been applied to many formulation projects with 
significant success as described below, and is a commonly used general assumption in 
pharmaceutical preformulation and formulation efforts.
Finding stabilizing conditions
By the same argument, we can also find stabilizing solution conditions (e.g. pH and ionic 
strength) for a liquid formulation by selecting conditions distant from EPD boundaries. 
More routinely, EPDs have assisted in the more standard stabilization and formulation 
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process, in which one finds solution conditions that increase stability as measured by the 
elevation of thermal unfolding/melting temperatures or reduction of aggregation24,73.
Using EPDs to investigate the similarity of two proteins
In the construction of EPDs, we perturb the system by varying solution conditions such as 
temperature, pH, and ionic strength, while measuring the system's response. Rather than 
focusing on transitions, we can also use an EPD in its entirety to gain additional information 
about the identity of the system's native form. We have found that EPDs of proteins of 
similar function do indeed appear similar.10-12,16,17 For example, the two heat shock 
proteins Hsc70 and gp96 have very little sequence homology, but demonstrate apparent 
phase changes in their EPDs which are nearly identical10.
Investigating protein dynamics
The intramolecular mobility of large molecular systems is a critical factor in their behavior, 
and a role in molecular recognition and enzymatic catalysis is now generally 
recognized.74-77 The relationship of the dynamic behavior of such systems to their stability 
remains, however, poorly understood.55 In this regard, EPDs have been employed to 
characterize the intramolecular dynamics of an IgG1 monoclonal antibody on a temperature-
pH perturbation grid.4 This study employed measurements sensitive to protein dynamic 
motions such as molecular tumbling, domain movement, and the degree of solvation. A 
combination of the following measurements was used: adiabatic compressibility determined 
from PPC, coefficient of thermal expansion determined from HRUS, REES, and rotational 
correlation times determined by TRFS anisotropy (see Table 1 for instrument abbreviations). 
An EPD was also generated based on the following time averaged methods: steady-state 
UV-IF, far-UV CD, light scattering, and ANS-EF. The latter methods are sensitive to 
alterations in protein secondary and tertiary structure. The EPDs from the dynamic and static 
measurements are shown in Figures 1G and 1H, respectively. In both EPDs, a very different 
conformational state was observed at pH values 3 and 4. The EPD based on the dynamics 
measurements is more complex overall, with low temperature events seen that are not 
present in the static EPD. This study indicates that measurements of protein dynamics 
potentially provide a more sensitive probe of protein stability and the effect of potential 
stabilizers. Related approaches are under further development in our laboratories.
Evaluating a Peptide Drug (Pramlintide)
The EPD method has not yet been used with small molecule pharmaceutical drugs, but it has 
been employed to characterize peptides. An analogue of amylin, the 37-residue peptide 
Pramlintide is currently used as an antihyperglycemic agent to treat diabetes. This peptide 
was characterized using a combination of CD, intrinsic Tyr fluorescence, second derivative 
UV absorbance, and optical density as a function of pH, temperature, and peptide 
concentration.7 Despite the fact that the data shows that the peptide is primarily unstructured 
at low concentration (confirmed by isotope exchange NMR), the EPDs are still surprisingly 
complex with distinct pH and temperature dependence reflecting very gradual structural 
alterations and some limited aggregation (Figure 7A-C). When the characterization was 
conducted over a wide range of Pramlintide concentrations, much more distinctive changes 
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in color were observed with transitions shifted to much lower temperatures and a narrower 
range of pH (Figure 7D-E).
Investigating the behavior of larger macromolecular complexes
The EPD approach enables visualization of high dimensional data, assisting in the 
determination of regularities and transition points. For the EPD approach to work, only two 
conditions are necessary, including that the system under study possess a well-defined 
structural identity, and that transitions in this identity are manifested in the data. A complete 
physical understanding of the processes governing the transitions is not necessary.
For example, viruses, virus like particles (VLPs), carbohydrate-conjugates, gene delivery 
vehicles, and other related macromolecular complexes have defined shapes, sizes, structural 
features and stability profiles. With selection of appropriate techniques, transitions in 
structure will be manifested in the data as multidimensional transitions in the measured 
values. These transitions can reflect significant structural changes that may be associated 
with changes in biological activity.
Signals obtained from such large systems, however, are the sum of signals from many 
subsystems which are themselves large. Thus, unlike smaller biomolecules such as purified 
proteins, it is unlikely that one will be able to directly relate the changes seen to actual 
molecular events in these larger macromolecular complexes. It may well be, however, that 
the experimental signals observed are due to subsystems that are present in multiple copies, 
and therefore reflect stress induced changes in key components of the complexes (for 
example, many copies of a viral coat protein within an intact virus.) Thus, such EPD data 
may still be quite useful in characterization studies. The EPD approach has, in fact, been 
applied successfully to the development and stabilization of numerous vaccines, including 
live attenuated bacterial vaccines,24 inactivated and live viruses and VLPs,21-23,25-27,29 as 
well as gene deliver complexes28,35.
Clostridium difficile Toxins and Toxoids
To further describe the EPD approach, we present a few representative examples of 
applications to biopharmaceutical drugs and vaccines based on proteins and larger 
macromolecular complexes. For example, studies using the EPD method were conducted of 
the A and B toxoids of Clostridium difficile, which are in clinical trials as a diarrheal 
vaccine.16 The proteins were characterized with CD, intrinsic and extrinsic (ANS) 
fluorescence, optical density, UV absorbance, and DLS. Clearly defined regions 
corresponding to folded protein, partially unfolded states as well as both soluble and 
unsoluble aggregates are observed (Figure 8A-B).16 Differences in EPDs are seen when the 
two toxins are crosslinked with formaldehyde to produce toxoids for use as vaccines (Figure 
8C-D) including enhanced thermal stability. Further utility of EPDs is illustrated by their use 
in pre-formulation characterization studies of the toxoid. Based on the apparent phase 
boundaries observed in the initial studies, a high throughput screening study was developed 
based on thermally induced aggregation of the proteins at low pH. A collection of 30 GRAS 
compounds was then screened and a number were identified which inhibited aggregation. To 
differentiate effects on conformational stability and aggregation, the proteins were also 
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studied with spectroscopic methods in the presence of presumptive stabilizers. Finally, 
stabilization studies of the toxoids on the surface of an aluminum salt adjuvant were 
conducted using DSC. Thus, a series of stabilizers were identified which were successfully 
employed in final formulations of a candidate C. difficile vaccine.
Norwalk Virus-like Particles
Multimeric biocomplexes can also be analyzed by use of EPDs. The most successful 
recombinant protein vaccines are, in fact, of the virus-like particle (VLP) type (i.e. Hepatitis 
B vaccine, HBV, and the human papillomavirus vaccine, HPV). One recent example of a 
candidate vaccine based on VLP technology is that of the Norwalk virus. This VLP consists 
of an icosahedral assembly of 180 copies of the VP1 capsid protein of the native virus with 
only a few copies of the VP2 protein also present. The resultant 38 nm particle was 
characterized by a combination of CD, DSC, intrinsic and extrinsic fluorescence, near UV 
absorbance and DLS, as a function of pH and temperature.23 A series of apparent phases 
could be identified in the EPD corresponding to a variety of conformational and aggregative 
states (Figure 9), including various states of dissociation of the particles. The precise nature 
of the latter was established by complementary transmission electron microscopy (EM) 
experiments. (This research and EPD were originally published in the Journal of Biological 
Chemisty. Ausar SF, Foubert TR, Hudson MH, Vedvick TS, Middaugh CR. 2006. 
Conformational stability and disassembly of Norwalk virus-like particles: Effect of pH and 
temperature. J Biol Chem 281:19478–88. © the American Society for Biochemistry and 
Molecular Biology.) Again, the EPD was used as a basis to select conditions to analyze the 
aggregation state of, in this case, the virus like particles. Compounds which were found to 
inhibit aggregation were also examined for their effects on ANS-EF, DSC and CD, with 
sucrose, trehalose, glutamate, and chitosan all found to both inhibit aggregation and 
conformationally stabilize the Norwalk VLP's.78 This study led to formulation of a 
candidate vaccine which has been successful in Phase II trials79,80.
Stabilization of Measles Virus
Larger macromolecular complexes such as killed and live viruses have also been 
characterized by the EPD approach. For example, the relatively unstable attenuated measles 
virus which is the basis for the important live virus measles vaccine has been examined 
using EPDs.24 This enveloped attenuated virus contains multiple copies of six different 
proteins as well as a ssRNA genome. Analysis is further complicated by the fact that the vast 
majority of viral particles have been inactivated during large scale preparation of the virus. 
Thus, the potential utility of biophysical studies is based on the assumptions that any change 
that affects the biological activity (immunogenicity in this case) of immediate interest is still 
detectable in a significant number of the remaining complexes and that individual 
measurements detect significant amounts of altered components (presumably due to their 
presence in multiple copies). While this is no doubt not always true, we have found such 
assumptions in most cases to be reliable. The measles virus was first purified from its crude 
vaccine preparation and then examined by the usual combination of spectroscopic and light 
scattering techniques.24 One additional EPD method not previously described involved the 
use of the fluorescent dye laurdan, a probe of membrane fluidity. The resulting EPD 
displays at least 6 regions of differing structure (Figure 10). (This research and EPD were 
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originally published in Kissmann J, Ausar SF, Rudolph A, Braun C, Cape SP, Sievers RE, 
Federspiel MJ, Joshi SB, Middaugh CR. 2008. Stabilization of measles virus for vaccine 
formulation. Human Vaccines 4:350–59.) An excipient screening method based on 
aggregation of the virus was used to identify potential stabilizers as determined by melting 
temperatures with the generalized polarization of laurdan fluorescence used as a 
confirmatory method. The compounds identified were then examined in cellular infectivity 
assays and served as a basis for a significant improvement in the thermal stability of the 
vaccine.
Polymeric and Liposomal Gene Delivery Systems
As a final example, polyplexes and lipoplexes containing plasmid DNA molecules 
complexed to various polymers and cationic lipids, respectively, were examined by the EPD 
method. Because of the high thermal stability of the DNA component, pH and ionic strength 
(rather than temperature) were used as the stress variables. Due to the electrostatic nature of 
the complexes, they were characterized over a wide range of positive and negative nitrogen 
to phosphate ratios using circular dichroism, extrinsic fluorescence with a DNA intercalating 
dye (YOYO-1) and dynamic light scattering.28 The EPDs derived for the polyplexes and 
lipoplexes lacked the sharp definition of those obtained in the proteinaceous systems 
described above, but still manifested distinct structural phases which were more complex 
than plasmid DNA alone (Figure 11). Application of EPD analyses to plasmid DNA and 
their delivery vehicle systems is still in its infancy, but appears to be a promising approach.
Current Research
The development and use of EPDs has provided a high throughput method to quickly 
determine relative higher order conformational states of biomolecules and larger 
macromolecular complexes over a large “search space” using multiple biophysical 
techniques. The optimal determination of regions of conserved structure in the EPD can, 
however, be hindered by several factors including the presence of noise in the 
measurements, transitions (during exposure to varying stress conditions) that occur very 
gradually and are thus difficult to detect, or the presence of important structural information 
from multiple measurements that cannot be readily reduced to 3 dimensions for display in 
the EPD.
The EPD method's speed of data collection can also be hindered by the size of the search 
space. Its practicality can be further limited by the complexity of data processing. In 
addition, in the absence of reliable automated pattern recognition, the need for an expert 
scientist to interpret the biophysical data to assign structural meaning to the various phases 
observed in the EPD, often on the basis of limited information, can also inhibit the method's 
speed, accuracy, and utility. Here we report on tactics under investigation in our laboratory 
to tackle and diminish such current limitations of the EPD approach.
A number of new pharmaceutical applications of EPDs are also being explored. These areas 
include extensions of the current approach to different stresses and a variety of 
pharmaceutical and vaccine dosage forms. In addition, possible applications of EPDs to 
describe the chemical stability of macromolecules will also be discussed. Finally, the EPD 
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methodology could potentially be applied to analytical comparability due to its ability to 
generate and analyze a large amount of biophysical data assessing the overall higher-order 
(secondary, tertiary and quaternary) structure of biomolecules as a function of solution 
conditions.
Maximum use of data
One typically provides the EPD method with a limited selection of peak positions, widths, or 
intensities, obtained from various experimental techniques. This results in a drastic reduction 
of the potential data set that precedes any global analysis. Data reduction in advance of 
processing is undesirable, since the excluded data may contain significant information 
concerning individual structural states and the transitions between them. More information 
would also allow the mathematical steps (PCA) to better distinguish signal from noise. To 
address these issues, one seeks a way to pass all of the data through a global analysis first, 
using minimal preprocessing. The first approach one might consider is to pass unprocessed 
spectra directly to the empirical phase diagram method. We have attempted this with FTIR 
and UV absorbance spectra, but the results do not resemble EPDs obtained by using the 
usual peak parameters (data not shown). Instead, the pH columns in the diagram show very 
large color differences from each other, dominating much smaller transitions in temperature 
or pH. The very large pH dependent signal is presumably due to changes in the charge state 
of amino acids.
We might also apply preprocessing methods that are known to highlight useful information 
without explicitly dropping data. The second derivative of a spectrum contains information 
on peak position and width. We can therefore use it to highlight information involving peak 
parameters. Another method is the use of a mid-pass Fourier filter to emphasize mid-size 
spectral features, while suppressing offsets and noise. To apply these methods, one simply 
filters spectra and passes them to the EPD method. A preliminary result is shown in Figure 
12E, in which the Fourier mid-pass method has been applied to the FTIR spectra of an IgG 
molecule. The spectra covered the 900 to 4000cm−1 range, and were measured over the 
temperature-pH search grid shown in the EPD.
Representing more than three dimensions
The error given by equation 1 can sometimes be large. Some criterion for what is too large, 
such as an error of 20% or greater, must be assigned and validated by the user. Large errors 
signal the presence of information that cannot be reduced to 3 dimensions. The color-coded 
EPD are limited by the colors the eye can perceive, given as ratios of red, green, and blue 
intensities. This is not due to a limitation in PCA or SVD: data can just as easily by 
projected into more than 3 dimensions. The challenge is to represent the extra dimensions. 
To represent more than 3 dimensions in each pixel, we can use the eye's ability to recognize 
shapes, textures, or other signals.
This is not to say that the number of phases that can be shown on an EPD is limited by the 
number of primary colors used to generate the EPD. Different ratios of red, green, and blue 
can generate a multitude of colors. Therefore a color coded EPD can display a multitude of 
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phases. The goal of displaying more than 3 dimensions in each pixel of an EPD is to reduce 
the role of projection and the accompanying error.
We show an example of 4-dimensional visualization in Figure 12F. In Figures 12A-C, we 
show the primary color images (red, green and blue) of an empirical phase diagram. They 
are ordered by descending significance from left to right. For axis information, see Figures 
12E and F. After solid red, green, and blue, we can use images containing structure that is 
smaller than the EPD pixels. This will represent information as changes in texture. Perhaps 
the easiest way to generate these images with small scale structure is through the use of 
different 2 dimensional harmonic modes, which is what we have done here. The projection 
error of the example in Figure 12 is significantly smaller for the four dimensional EPD than 
for the 3-dimensional one. In this case, the fourth principal component shows an additional 
transition between low and mid range temperatures.
The main reason for expressing information from the EPD method with three colors or 
selected textures is to exploit the visual processing power of the human eye and brain to 
segment the EPD into different phases. The traditional “black and white” representation of 
different regions in a phase diagram is also perfectly acceptable. It amounts to assigning a 
name, or number, for each distinctly observed and coherent region of the system's physical 
properties. The 15 known phases of ice are conventionally represented by 15 numbers 
labeling regions of the pressure-temperature diagram.
Machine learning techniques exist and are being developed to perform the task of 
segmenting an image. Among the techniques are clustering, support vector machines 
(SVM's), and Kohonen networks. The main advantage of these techniques is that they can 
operate on high dimensional data, reducing the role of projection and its accompanying 
error. In Figure 12F we show the results of a simple image segmentation. We have selected 
5 characteristic points on the phase diagram to represent the 5 visible phases. Then, the 
remaining temperature-pH points have been categorized by their euclidean distance from the 
characteristic points, where the distance is calculated in measurement space. This is one 
example; mathematics and computer science possess an abundance of methods designed to 
recognize and organize information.
Information management
After an EPD is generated, the colors must be assigned meaning based on the information in 
the experimental data. The standard approach is for a scientist to assign meaning to the 
colors based on inspection of the original experimental data and the principal components 
given by PCA. As discussed earlier, however, local inspection of multidimensional data is 
difficult and does not maximize its utility. It should be better to pursue the assignment of 
meaning within a general mathematical framework, allowing data to be automatically 
correlated with observables of interest, such as aggregation pathways and known protein 
conformational states. Working within a general mathematical framework will also allow 
determination of the significance of types of information for a given task, so that data 
collection can be streamlined by the selection of optimal techniques, wavelengths, and 
integration times.
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Relevant mathematics will need to be provided with a starting point. Fortunately, much is 
known about the determination of protein conformational state from spectroscopic 
techniques. Also, many proteins have been fully characterized with the EPD approach. The 
main difficulty in getting started with an automated approach is that raw multi-instrument 
digital data sets from different experiments tend to be organizationally very complex. They 
involve multiple data formats and missing data points due to instrument hiccups and 
differing experimental protocols. The interpretation of an archived data set often requires 
additional information that must be located. Without an organizing software framework it is 
difficult to enforce uniform, comprehensive documentation and organization of different 
biophysical data from diverse sources.
We are working on two solutions to address this issue. One approach consists of a point-
and-click program, used for generating phase diagrams. In this interface the user organizes 
the data and generates phase diagrams. The data are automatically saved with full 
documentation in the desired format. The other approach is automated, consisting of a 
framework for importing, processing, and plotting complex information. This automated 
approach is guided by a short user-programmable script.
Automation
As described in the introduction, modern biopharmaceutical drug formulation challenges, 
including accelerated time-lines and limited material availability, can result in suboptimal 
formulations or even product failure due to instability. Because of these challenges, one 
wishes to explore as much of a search space as possible, using mathematical techniques to 
obtain the maximum possible amount of information from the data. This collection of 
techniques can also automate the interpretation of data. Machines and mathematics excel at 
quickly obtaining and processing massive amounts of data. To this end, it is our goal to 
automate data collection and interpretation as much as possible, so that the formulation 
scientist's participation will consist primarily of determining goals, methods, preparing 
experiments and designing final formulations based on the results. In the next level of 
automation, scientists would still determine goals and methods, but the machine would 
choose and prepare its own experimental test cases.
An automated method would potentially work roughly as follows. The equipment would 
consist of a modern liquid handler, such as the Labcyte Echo®, robotically coupled to a 
microplate reader, and controlled via a suitable programming interface. First, spectroscopic 
measurements of the native form of a macromolecule would be characterized over a region 
in search space. By characterize we mean finding the simplest accurate mathematical 
description. This would be akin to a more sophisticated version of the empirical phase 
diagram. To cover the search space we would use an advanced “Design of Experiment” 
technique known as “adaptive sampling”.81 Essentially, the customary grid of points in 
search space (the test cases) would be replaced by a growing set of points, in which each 
new point is chosen based on the information contained in previous points. Next, 
measurements of the macromolecule after accelerated stress would be characterized. In this 
second step, prior information would be available from both the initial characterization and 
from the characterization of other macromolecular systems. The prior information would be 
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used to optimally distribute the test cases in search space, reducing the required number of 
such studies. We mention this idea because it is the natural end point of current research. At 
present, however, it is only hypothetical.
New pharmaceutical applications of EPDs
Several new pharmaceutical applications for EPDs are currently being explored in our 
laboratories. One straight forward new application is the extension of the current EPD 
approach to different stresses and different dosage forms. As shown in Table 2, most EPDs 
generated to date have evaluated liquid formulations using temperature, solution pH, ionic 
strength and macromolecular concentration as the primary stresses to perturb the structure of 
a biomolecule or macromolecular complex. Additional environmental stresses that could 
easily be adapted to EPD analysis include freeze-thaw, lyophilization and shaking/agitation. 
For example, in terms of development of a frozen liquid or lyophilized dosage form, the 
effect of multiple freeze/thaw steps as well as the effect of freeze-drying cycles and 
reconstitution could be evaluated using the same biophysical techniques described above. 
Measurements of protein conformational integrity and stability in the solid state itself could 
also be explored by EPDs using FTIR and Raman spectroscopies, as well as DSC. 
Identification of phase transition regions could then be used to setup an excipient screening 
approach for these stresses.
The EPD approach could also be applied to develop a better understanding of different 
degradation pathways as a function of environmental conditions. In the case of shaking or 
agitation stress, different shaking speeds, or rotations per minute, could replace temperature 
as a stress factor. Moreover, new biophysical analytical approaches could be added 
including detection of protein particles by multiflow digital imaging (MFI) or Nanosight 
technology. If combined with SE HPLC and OD350 measurements, an EPD could be 
generated to better characterize protein aggregation and subvisible particle formation. In 
addition, the EPD approach could also be used to examine chemical stability of 
macromolecules. For example, the rate and extent of specific Asn deamidations or Met 
oxidations in a protein could be mapped as a function of temperature and solution pH. These 
“chemical” EPDs could also be overlaid with conformational EPDs to better understand the 
inter-relationships(s) between chemical and physical stability.
Finally, the unique ability of the EPD method to use a wide variety of biophysical 
techniques to generate and analyze a large amount of data assessing overall structural 
integrity and conformational stability of biomolecules could potentially be applied to 
analytical comparability during development of different biopharmaceutical drugs and 
vaccines. For example, since the EPD method does not require much protein (1-10 mg), and 
since availability of protein is often a limiting factor in early formulation development, the 
generation of EPDs for different candidate molecules could be used as a tool to select the 
best candidate in terms of “developability” properties such as stability and solubility 
profiles. Moreover, during later development, process and product changes are usually 
required to scale up the process for commercial use. These changes often lead to subtle or 
more dramatic changes in the biomolecules post-translational modifications or degradation 
profiles (e.g., glycosylation pattern or extent of oxidation of a specific Met residue). The 
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ability to monitor the effect of these changes on the overall structural integrity and 
conformational stability of biomolecules remains an area of ongoing interest, especially as a 
possible surrogate for more complex assessments of conformation such as biological assays. 
The ability of the EPD approach to compare the same biomolecule with differing 
glycosylation patterns and/or chemically altered amino acid residues is currently being 
evaluated.
One challenge with this approach is to better assess the precision of the phase identification 
stage of the EPD methodology. For example, it is important to establish if the differences 
observed between two protein preparations is greater than the differences observed between 
multiple measurements of the same protein preparation. In addition, as described in Figure 
12 in the previous section, additional higher dimensional information can be added to the 
standard EPD through the use of changes in texture. This approach, although not routinely 
used to date, could eventually provide additional structural information for EPDs being 
generated for the purpose of analytical comparability. Finally, multiple environmental 
stresses could be utilized (temperature, pH, ionic strength, agitation) to build up a more 
comprehensive database to compare the structural integrity and conformational stability of a 
biomolecule prepared from different cell-lines or cell culture/purification/formulation 
processes.
Conclusion
Modern biopharmaceutical drug development time-lines, combined with limited availability 
of sufficient material, can result in a variety of challenges for the formulation scientist 
attempting to rapidly design and develop stable dosage forms for clinical use. Our quest is to 
enable faster and more thorough screening searches of stabilizing agents and solution 
conditions by more fully utilizing the information contained in data sets from experimental 
methods which examine the structural integrity and conformational stability of 
macromolecules and their complexes. We strive to explore as much of the available search 
space as possible, using mathematical techniques to obtain the maximum amount of 
information from the data.
The interpretation of large data sets is made difficult by high dimensionality and the 
existence of conflicting information. Formulation scientists typically determine transitions in 
macromolecular structure by using techniques that look at the data locally. Unfortunately, 
global features on high-dimensional data spaces are not always revealed by such local data 
inspection. Each experimental method provides a picture of one or more different aspects of 
the target macromolecule. As indicated previously, this situation is similar to the tale of the 
blind men and the elephant, where the the elephant represents the macromolecular drug or 
vaccine, and the various blind men touching different parts of the elephant represent the 
different experimental methods. The formulation scientist must assimilate all of the 
conflicting information into a single picture of what an elephant must look like. The lack of 
an accessible global picture of the data can result in an undesirable degree of approximation 
of macromolecular transition points brought on by different environmental stresses.
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A standard way to reduce the dimensionality of data is by use of the singular value 
decomposition (SVD). SVD returns a number of spatial axii, defining spaces on which the 
data can be approximated. The approximation error can be minimized by using a space 
defined by the most important spatial axii. The projection onto that space is the best possible 
approximation to the data that can be made on the number of dimensions retained. To 
provide a convenient visual image, the resulting low-dimensional positions can be converted 
into colors or textures and presented as an image. Such an image is called an empirical phase 
diagram (EPD). The empirical phase diagram method guides the formulation scientist by 
assisting in the visualization of high dimensional information, the determination of 
macromolecule identity and transition points, and a reduction of the size of search spaces. 
This approach is quite different from that of the commonly used “Design of Experiment” 
approach which lacks high density data and produces holes in the picture produced.
The EPD method has found many uses in the optimization of various types of formulations, 
and many case studies have been published concerning their application to various 
macromolecular complexes such as viruses and lipoplexes. The EPD approach has been 
extended over time to include the addition of multiple biophysical measurement techniques 
and different search space variables. The use of empirical phase diagrams is not limited to 
proteins and plasmid DNA molecules, but includes larger macromolecular complexes such 
as viruses and whole cells. One can potentially incorporate almost any kind of information, 
including measurements of structural dynamics, aggregation kinetics, chemical stability or 
biological function as well as other common pharmaceutical variables of stress such as 
agitation and freeze/thaw cycles. Empirical phase diagrams have also been demonstrated to 
contain information concerning the functional and evolutionary relationships of 
proteins.10-12,16,17 Using EPDs, macromolecule identity has been found to be conserved 
over contiguous regions of search space.
The use of EPDs has brought us to a vantage point where we see clear evidence for a 
previously unrealized treasure trove of hidden information concerning the higher order 
structural integrity and conformational stability of biomolecules and larger macromolecular 
complexes such as viruses and lipoplexes. Much work remains, however. Data consists of 
combinations of different types of information. Each type is mixed with other types in 
complex ways, and has its own meaning, prominence in the data, and significance for the 
task at hand. The inter-relationships between these factors is complex, requiring systematic 
study within a mathematical framework. However, the journey will be worth the effort. The 
exhaustion of information in macromolecular data sets suggests a future in which access to 
new information leads to novel formulation and stabilization methods.
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In this Appendix we state the properties of the singular value decomposition (SVD) and the 
connection between the singular values and the reconstruction error. Many mathematical 
software packages have a command for calculating SVD's.
Standardization and preprocessing of data produces an l×m matrix Dij of data, where indices 
i=1…l, j=1…m. The singular value decomposition of D is
(2)
where d=Min(l, m). The decomposition exists for any matrix, whether real or complex, 
square or rectangular. The matrices Uiα and Vαj are calculated by solving for the 
eigenvectors of the covariance matrices DDT and DTD:
where Uα is a column of the matrix Uiα, and Vα is a row of the matrix Vαj. For complex 
matrices replace the transpose DT by the adjoint D†.
Both DDT and DTD are real symmetric, or complex self-adjoint, and positive definite. The 
numbers Wα, called singular values, are by convention real and positive by a choice of sign 
(or complex phase) of the eigenvectors. Also by convention, the singular values are sorted in 
order of decreasing size, and the eigenvectors are sorted accordingly.
The rows of Vαj are normalized. Since they are eigenvectors, they are orthogonal to one 
another:
Likewise for the columns of Uiα:
The rows of V and the columns of U are called singular vectors. When D is real, U and V 
are also real.
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The decomposition is unique up to a complex factor chosen for each pair of eigenvectors:
Even when D is real, the signs of the singular vectors are not uniquely determined by the 
decomposition. This is an additional reason why similar data sets can produce phase 
diagrams with different colors.
Equation 2 can be read either as a matrix product or as a sum of matrices, each identified by 
the index α. The second interpretation is helpful. These summand matrices exist in the 
vector space of l×m matrices. The natural vector norm in this space is the Frobenius (or 
Hilbert-Schmidt) norm ║M║, which for an l×m matrix M is defined as
The norm of each summand in Equation 2 is Wα :
Since the numbers Wα are sorted in decreasing order, Equation 2 is a series of corrections 
decreasing in size. For many data sets, the most common result is that the data can be 
approximated well by a sum over just the top few summands α, since the largest singular 
values tend to be much larger than the rest. If we use the top n singular values, where 1≤n<d, 
Equation 2 becomes
where D̃ is the approximated data.
In the vector space of l×m matrices, the summands are orthogonal:
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Since the summands are orthogonal and their individual norms are Wα, the norm of the 
partial sum D̃ is the same as the ordinary vector norm of the Wα included in the sum:
The RMS reconstruction error, directly expressed as
can also be expressed as
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An empirical phase diagram (EPD) assists in the visualization of a data set resulting from 
the methods listed in Table 1. Figures A-F show measurements of an IgG1 monoclonal 
antibody collected at pH 3 (black), 4 (red), 5 (green), 6 (yellow), 7 (blue), and 8 (magenta). 
(A) CD molar ellipticity at 218 nm, (B) UV intrinsic fluorescence (UV-IF) peak position and 
(C) intensity, (D) tryptophan fluorescence lifetime, (E) static light scattering (SLS), and (F) 
ANS extrinsic fluorescence (ANS-EF) intensity. Error bars in (A-C and E-F) are from three 
independent experiments.4 Figure (G) shows an EPD based on the above data. Figure (H) 
shows an EPD based on protein dynamics measurements (data not shown, see the 
applications section for more information).
Maddux et al. Page 35























Empirical phase diagrams have found many uses in the optimization of various types of 
formulations. Many case studies have been published concerning their application to various 
systems and their extension by the addition of measurement techniques and search space 
variables. The EPDs in this figure are only from papers published in the Journal of 
Pharmaceutical Sciences. Many more EPDs have been published in other journals or 
generated in proprietary studies. Refer to Table 2 for more information concerning each 
EPD. All EPDs in this diagram have temperature (°C) as the vertical axis. Diagrams 1-35 
use pH on the horizontal axis, and diagrams 36-40 have the indicated stress variables on the 
horizontal axis. All EPDs in this article have been reformatted for uniform layout.
Maddux et al. Page 36























An illustration of three types of spaces, using simulated data. In Figure (A), four pH values 
define a one dimensional search grid in search space, and ratios of secondary structure type 
illustrate a protein phase space. Figure (B) shows how two measurement types define a 
measurement phase space. The transition pH values disagree when we plot measurements 
separately, as in Figures (C) and (D). A plot in measurement phase space (B) synthesizes the 
information, but will not work as a visual aid for high dimensional data.
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Principal Components Analysis can be used to project two dimensions into one. The 
procedure works the same way for high dimensional data (see Figure 5 and 6). We will use 
the simulated data shown in Figure 3B. (A): First we center the measurements at the origin, 
since we are interested in transitions, not average values. (B): Next we normalize each 
measurement so that they have equal influence on the result. (C): Finally, we use the 
Singular Value Decomposition (SVD) to find the optimal line for projection (shown in 
blue). (D): If we plot the position along the blue line, we see that the difference is greatest 
between pH values 5 and 6.
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An example of the Singular Value Decomposition (SVD) using simulated data. (A) is a plot 
of three simulated peak shifts Δλ1, Δλ2, and Δλ3 as a function of temperature. If we could 
perceive two dimensions but not three, the transition between 50°C and 70°C might be 
difficult to see. Therefore, we would want to reduce the data to two dimensions in a way that 
optimally retains the information in the original data set. (B) shows the plane (in pink) 
which gives the optimum 2D projection. This plane is determined by SVD, and is defined by 
the vectors X1 and X2(in blue). The projection error is shown as red lines. (C) is a 2 
dimensional plot of the same data, using the positions within the pink plane. This is a plot of 
matrix A (see text). (D) shows the optimal one dimensional projection, demonstrating that 
the error is larger. This plot uses the first column of matrix A (see text).
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Illustration of the steps in the Empirical Phase Diagram method, using simulated data. (A): 
Choose a search space and a search grid. In this case, the search space is 2 dimensional, 
varying temperature and pH. In each dimension, two values have been chosen, forming a 
grid. (B): Collect data at each point of the search grid. The data in this example is 5 
dimensional. (C): Standardize the data and project it into 3 dimensions. (D): Rescale to the 
range (0,1), and express as a color. (E): Transform the colors into an image.
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Empirical phase diagrams(EPDs) of the peptide drug pramlintide at low and high 
concentration,7 and concentration dependence at pH 4. Low concentrations (0.088 mg/ml) 
are represented in A-C. The experimental techniques used to construct A-C were as follows: 
(A) second derivative UV absorbance peak shift and OD350, (B) same as (A), adding 
fluorescence intensity and peak shift, (C) same as (B), adding the CD change at 204 nm. The 
peptide at high concentration (8.8 mg/mL) is represented in (D), using the same 
experimental techniques as (B). An EPD at pH 4 as a function of peptide concentration is 
shown in (E), using the same experimental techniques as (B).
Maddux et al. Page 41























An empirical phase diagram for two toxins and toxoids of Clostridium difficile, created 
using OD350, UV-IF, ANS-EF, and CD data.16 Data were normalized simultaneously for the 
corresponding toxin and toxoid. (A) Toxin A; (B) Toxin B; (C) Toxoid A; (D) Toxoid B.
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Empirical phase diagram for Norwalk virus-like particles (NV-VLPs) based on UV 
absorbance, intrinsic and extrinsic fluorescence and CD results.23 Four distinct phases (P) of 
the NV-VLP were observed: P1, native, intact form; P2, disassembled; P3, soluble VP1 
oligomers; P4, aggregated. The nature of the protein in the various phases was confirmed by 
transmission electron microscopy studies.
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Empirical phase diagram of attenuated Measles virus.24 Data used to generate the EPD were 
measurements of mean effective diameter by DLS, intensity of 562 nm light scattered at 90°, 
CD at 222 nm, intrinsic fluorescence intensity at 322 nm, ANS peak position, ANS 
fluorescence intensity at 469 nm and generalized polarization of laurdan fluorescence.
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Ionic strength-pH empirical phase diagrams of various nonviral gene delivery complexes 
formed between plasmid DNA and four cationic carriers.28 Each EPD has pH as the 
horizontal axis and ionic strength (mM) as the vertical axis. The experimental techniques 
used were DLS, CD, and YOYO-1 EF.
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When the projection error is large it can be reduced by incorporating more dimensions. In 
(A)-(C), we show the primary color images (red, green and blue) of an empirical phase 
diagram. They are ordered by descending significance from left to right. For axis 
information, see (E) and (F). After solid red, green, and blue, we can use images containing 
structure that is smaller than the individual phase diagram blocks. This will represent high 
dimensional information as changes in texture. Such an image is shown in (D). (E) is a 3 
dimensional empirical phase diagram of IgG, using FTIR spectra which have been 
preprocessed with a Fourier filter to emphasize mid-size spectral features. (F) is a 4 
dimensional empirical phase diagram of the same data as (E), showing fourth dimensional 
information as changes in texture. Notice that the reconstruction error has decreased. The 
diagram has also been automatically segmented into 5 parts (see text).
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Table 2
Biomolecules and larger macromolecular complexes, analytical techniques and environmental stress 
conditions evaluated by empirical phase diagrams. See Table 1 for definitions of the technique abbreviations.
Target Techniques Search Space Figure Ref.
Measles virus CD, DLS, SLS, EF pH, Ta 10 24
Human respiratory syncytial virus CD, UVAS, OD350, UV-IF pH, T 25
Live atten. Ty21a bacterial typhoid vaccine CD, EF pH, T 29
Adenovirus type 5 (Ad5) UVAS, DLS, UV-IF, EF pH, T 2.32, 2.33 26
Recombinant ricin toxin A-Chain vaccine CD, UF-IF, EF pH, T 2.20, 2.31 73
Adenovirus type 2 (Ad2) CD, UVAS, OD350, DLS… pH, T 2.34 27
Hepatitis C virus envelope glycoprotein E1 CD, DLS, UV-IF, EF pH, T, Sa 2.37 - 2.40 21
Clostridium difficile toxins and toxoids CD, OD350, UV-IF, EF pH, T 8 16
Type III secretion system tip proteins CD, UVAS, UV-IF, EF pH, T 14
Type III secretion system needle proteins CD, UVAS, EF pH, T 17
Malaria antigen EBA-175 RII-NG CD, UV-IF, EF pH, T 15
H1N1 influenza virus-like particles CD, DLS, EF pH, T 2.25 22
Norwalk virus-like particles CD, UVAS, UV-IF, EF pH, T 9 23
Nonviral gene delivery complexes CD, DLS, EF pH, Ia 11 28
Human Inteferon-β-1a CD, UVAS, UV-IF, EF pH, T 2.12, 2.19 5
Bovine granulocyte colony stim. factor UVAS pH, T 2.26 6
Immunoglobulin-G (IgG) CD, EF, PPC, HRUS, TRFS… pH, T 1 4
Pramlintide (antihyperglycemic peptide) CD, UVAS, OD350, UV-IF pH, T, Ca 7 7
Monoclonal antibodies CD, UVAS, OD350, UV-IF T, C 2.36 8
Clostridium botulinum type A neurotoxin CD, UV-IF, EF pH, T 9
Molecular chaperones Hsc70 and gp96 CD, UVAS pH, T 10
Human fibroblast growth factor 1 (FGF-1). CD, UVAS, UV-IF, EF pH, T, S 2.6 - 2.11 11
Fibroblast growth factor 20 (FGF-20) CD, UVAS, UV-IF pH, T 12
rPA of B. anthracis CD, UV-IF, EF pH, T 2.31, 2.35 13
Recombinant vault particles CD, UV-IF, EF pH, T 2.30 18
Recombinant human gelatins CD, UV-IF, UVAS pH, T 2.21 - 2.24 19
EC5 domain of E-Cadherin CD, UV-IF, UVAS pH, T, N/Ra 2.27 - 2.29 20
a
T = Temperature, I = Ionic Strength, C = Concentration, S = Stabilizer, N/R = Native/Reduced
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